Who are Alnylam Pharmaceuticals, Inc.'s main suppliers?

Alnylam Pharmaceuticals, Inc. (ALNY) key suppliers include: REGENERON, ROCHE, Dyne Therapeutics, Inc., iBio, Inc., Ionis Pharmaceuticals, Inc. and 9 more. View the full supplier network at chainsifter.com/chain/ALNY.

Who are Alnylam Pharmaceuticals, Inc.'s major customers?

Alnylam Pharmaceuticals, Inc. (ALNY) key customers include: Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., AstraZeneca PLC, AstraZeneca PLC, Dyne Therapeutics, Inc. and 19 more. View the full customer network at chainsifter.com/chain/ALNY.

What sector is Alnylam Pharmaceuticals, Inc. in?

Alnylam Pharmaceuticals, Inc. (ALNY) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Alnylam Pharmaceuticals, Inc. Supplier List (ALNY): 14 Verified Suppliers

14Suppliers

24Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Alnylam Pharmaceuticals, Inc. (ALNY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

41Total relationships

1Distinct source URLs

7High confidence

0.745Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Alnylam Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
REGENERON	REGENERON	90%	In November 2022, Regeneron exercised its right under the C5 Co-Co Collaboration Agreement to opt-out of the further development and commercialization of cemdisiran monotherapy.
ROCHE	ROCHE	85%	As of the Effective Date, we identified the following promises in the Roche Agreement that were evaluated under the scope of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contrac…
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from DYN grap…
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. Ther…
IONS	Ionis Pharmaceuticals, Inc.	72%	Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS g…
NTLA	Intellia Therapeutics, Inc.	72%	Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain a…
NVS	Novartis AG	72%	Reciprocal relationship from NVS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVS grap…
PEPG	PepGen Inc.	72%	Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise comp…
RNA	Atrium Therapeutics, Inc.	72%	Reciprocal relationship from RNA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from RNA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from RNA grap…
SRPT	Sarepta Therapeutics, Inc.	72%	Reciprocal relationship from SRPT graph: exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned product…
TNYA	Tenaya Therapeutics, Inc.	72%	Reciprocal relationship from TNYA graph: occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Contract Li…
VEEV	Veeva Systems Inc.	72%	Reciprocal relationship from VEEV graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VEEV graph: Consulting provides strategic consulting services and solutions that are oft…
VIR	Vir Biotechnology, Inc.	72%	Reciprocal relationship from VIR graph: clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial v…
VOR	Vor Biopharma Inc.	72%	Reciprocal relationship from VOR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VOR graph: focused sales, marketing and commercial support infrastructure to sell, or par…

Alnylam Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
REGN	Regeneron Pharmaceuticals, Inc.	85%	bal, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targe…
REGN	Regeneron Pharmaceuticals, Inc.	85%	Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN g…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, whi…
AZN	AstraZeneca PLC	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
DYN	Dyne Therapeutics, Inc.	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
IBIO	iBio, Inc.	72%	Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Ver…
IONS	Ionis Pharmaceuticals, Inc.	72%	Reciprocal relationship from IONS graph: ible to receive tiered royalties up to 30 percent on net sales. From inception through December 31, 2025, we have generated more than $125 million in payments…
LLY	Eli Lilly and Company	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from LLY grap…
NTLA	Intellia Therapeutics, Inc.	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
NTLA	Intellia Therapeutics, Inc.	72%	Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA g…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVO graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, whi…
NVO	Novo Nordisk A/S	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
SLN	Silence Therapeutics plc	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
SLN	Silence Therapeutics plc	72%	Reciprocal relationship from SLN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SLN graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, whi…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALNY graph: yasthenia gravis and geographic atrophy. In August 2025, Regeneron announced that cemdisiran monotherapy met the pri…
SNYNF	Sanofi	72%	yasthenia gravis and geographic atrophy. In August 2025, Regeneron announced that cemdisiran monotherapy met the primary and key secondary endpoints in the Phase 3 NIMBLE clinical trial in generalize…
SRPT	Sarepta Therapeutics, Inc.	72%	Reciprocal relationship from SRPT graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and finan…
SRPT	Sarepta Therapeutics, Inc.	72%	ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. …
VIR	Vir Biotechnology, Inc.	72%	, the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable co-co collaboratio…
VIR	Vir Biotechnology, Inc.	72%	Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR grap…
VKTX	Viking Therapeutics, Inc.	72%	Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VKTX g…
F-HOFFMANN-LA-ROCHE-LTD	F-HOFFMANN-LA-ROCHE-LTD	62%	antially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December 31, 2025, which were included in our Annual Report on Form …

Alnylam Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ALNY-DEBT-7692	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
ALNY-DEBT	Debt stack $677.7M	90%	Market cache reports total debt of $677.7M.

Alnylam Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ALNY-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 796 tracked holders.

Alnylam Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
FHTX	Foghorn Therapeutics Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2

Alnylam Pharmaceuticals, Inc. Supply Chain